506 related articles for article (PubMed ID: 35287591)
1. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib.
Ding P; Wu J; Wu H; Sun C; Guo H; Lowe S; Yang P; Tian Y; Liu Y; Meng L; Zhao Q
BMC Gastroenterol; 2023 Jan; 23(1):23. PubMed ID: 36690935
[TBL] [Abstract][Full Text] [Related]
3. Predictive Effect of Systemic Immune-Inflammation Index Combined With Prognostic Nutrition Index Score on Efficacy and Prognosis of Neoadjuvant Intraperitoneal and Systemic Paclitaxel Combined With Apatinib Conversion Therapy in Gastric Cancer Patients With Positive Peritoneal Lavage Cytology: A Prospective Study.
Ding P; Yang P; Sun C; Tian Y; Guo H; Liu Y; Li Y; Zhao Q
Front Oncol; 2021; 11():791912. PubMed ID: 35127498
[TBL] [Abstract][Full Text] [Related]
4. Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy.
Fan R; Chen Y; Xu G; Pan W; Lv Y; Zhang Z
Front Oncol; 2023; 13():996312. PubMed ID: 37077828
[TBL] [Abstract][Full Text] [Related]
5. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Xu J; Jiang H; Pan Y; Gu K; Cang S; Han L; Shu Y; Li J; Zhao J; Pan H; Luo S; Qin Y; Guo Q; Bai Y; Ling Y; Yang J; Yan Z; Yang L; Tang Y; He Y; Zhang L; Liang X; Niu Z; Zhang J; Mao Y; Guo Y; Peng B; Li Z; Liu Y; Wang Y; Zhou H;
JAMA; 2023 Dec; 330(21):2064-2074. PubMed ID: 38051328
[TBL] [Abstract][Full Text] [Related]
6. Prediction of severe radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma using the combined systemic immune-inflammatory index and prognostic nutritional index.
Song J; Wen Y; Liang L; Lv Y; Liu T; Wang R; Hu K
Eur Arch Otorhinolaryngol; 2024 May; 281(5):2627-2635. PubMed ID: 38472492
[TBL] [Abstract][Full Text] [Related]
7. Combined systemic inflammatory immunity index and prognostic nutritional index scores as a screening marker for sarcopenia in patients with locally advanced gastric cancer.
Ding P; Lv J; Sun C; Chen S; Yang P; Tian Y; Zhou Q; Guo H; Liu Y; Zhao Q
Front Nutr; 2022; 9():981533. PubMed ID: 36046129
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial.
Guo H; Ding P; Sun C; Yang P; Tian Y; Liu Y; Lowe S; Bentley R; Li Y; Zhang Z; Wang D; Li Y; Zhao Q
Front Oncol; 2022; 12():927781. PubMed ID: 36091139
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.
Wang F; Qu A; Sun Y; Zhang J; Wei B; Cui Y; Liu X; Tian W; Li Y
Br J Radiol; 2021 Aug; 94(1124):20201088. PubMed ID: 34260297
[TBL] [Abstract][Full Text] [Related]
13. Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy.
Zhang Y; Kong FF; Zhu ZQ; Shan HX
BMC Cancer; 2023 Mar; 23(1):225. PubMed ID: 36894927
[TBL] [Abstract][Full Text] [Related]
14. Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients.
Ma C; Yu R; Li J; Guo J; Xu J; Wang X; Liu P
J Surg Oncol; 2022 Mar; 125(4):754-765. PubMed ID: 34811745
[TBL] [Abstract][Full Text] [Related]
15. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.
Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W
BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
[TBL] [Abstract][Full Text] [Related]
17. Comparison and exploration of the prognostic value of the advanced lung cancer inflammation index, prognostic nutritional index, and systemic immune-inflammation index in newly diagnosed diffuse large B-cell lymphoma.
Liu T; Ye F; Li Y; Liu A
Ann Palliat Med; 2021 Sep; 10(9):9650-9659. PubMed ID: 34628890
[TBL] [Abstract][Full Text] [Related]
18. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
[TBL] [Abstract][Full Text] [Related]
19. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
20. Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer.
Yang G; Liu P; Zheng L; Zeng J
Front Surg; 2022; 9():1004687. PubMed ID: 36406359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
